Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects JZ Long, W Li, L Booker, JJ Burston, SG Kinsey, JE Schlosburg, FJ Pavón, ... Nature chemical biology 5 (1), 37-44, 2009 | 999 | 2009 |
A genetic determinant of the striatal dopamine response to alcohol in men VA Ramchandani, J Umhau, FJ Pavon, V Ruiz-Velasco, W Margas, H Sun, ... Molecular psychiatry 16 (8), 809-817, 2011 | 315 | 2011 |
Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-3-hexyl-1H-1, 2, 4-triazole–LH 21 FJ Pavon, A Bilbao, L Hernández-Folgado, A Cippitelli, N Jagerovic, ... Neuropharmacology 51 (2), 358-366, 2006 | 134 | 2006 |
Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats A Sayd, M Antón, F Alén, JR Caso, J Pavón, JC Leza, ... International Journal of Neuropsychopharmacology 18 (6), pyu111, 2015 | 105 | 2015 |
Oleoylethanolamide prevents neuroimmune HMGB1/TLR4/NF‐kB danger signaling in rat frontal cortex and depressive‐like behavior induced by ethanol binge administration M Antón, F Alén, R Gomez de Heras, A Serrano, FJ Pavón, JC Leza, ... Addiction biology 22 (3), 724-741, 2017 | 100 | 2017 |
Plasma profile of pro‐inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co‐morbidity P Araos, M Pedraz, A Serrano, M Lucena, V Barrios, N García‐Marchena, ... Addiction biology 20 (4), 756-772, 2015 | 99 | 2015 |
Reduction of body weight, liver steatosis and expression of stearoyl‐CoA desaturase 1 by the isoflavone daidzein in diet‐induced obesity A Crespillo, M Alonso, M Vida, FJ Pavón, A Serrano, P Rivera, ... British journal of pharmacology 164 (7), 1899-1915, 2011 | 97 | 2011 |
Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH‐21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats FJ Pavón, A Serrano, V Perez‐Valero, N Jagerovic, ... Journal of neuroendocrinology 20, 116-123, 2008 | 94 | 2008 |
Peroxisome proliferator-activated receptors: Experimental targeting for the treatment of inflammatory bowel diseases J Decara, P Rivera, AJ López-Gambero, A Serrano, FJ Pavón, E Baixeras, ... Frontiers in pharmacology 11, 730, 2020 | 90 | 2020 |
A place for the hippocampus in the cocaine addiction circuit: Potential roles for adult hippocampal neurogenesis E Castilla-Ortega, A Serrano, E Blanco, P Araos, J Suárez, FJ Pavon, ... Neuroscience & Biobehavioral Reviews 66, 15-32, 2016 | 90 | 2016 |
The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats A Serrano, I Del Arco, FJ Pavón, M Macías, V Perez-Valero, ... Neuropharmacology 54 (1), 226-234, 2008 | 88 | 2008 |
Differential effects of single versus repeated alcohol withdrawal on the expression of endocannabinoid system‐related genes in the rat amygdala A Serrano, P Rivera, FJ Pavon, J Decara, J Suárez, ... Alcoholism: Clinical and Experimental Research 36 (6), 984-994, 2012 | 79 | 2012 |
Pharmacological administration of the isoflavone daidzein enhances cell proliferation and reduces high fat diet-induced apoptosis and gliosis in the rat hippocampus P Rivera, M Pérez-Martín, FJ Pavón, A Serrano, A Crespillo, M Cifuentes, ... PLoS One 8 (5), e64750, 2013 | 78 | 2013 |
Role of the satiety factor oleoylethanolamide in alcoholism A Bilbao, A Serrano, A Cippitelli, FJ Pavón, A Giuffrida, J Suárez, ... Addiction biology 21 (4), 859-872, 2016 | 74 | 2016 |
Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat J Suárez, P Rivera, S Arrabal, A Crespillo, A Serrano, E Baixeras, ... Disease models & mechanisms 7 (1), 129-141, 2014 | 69 | 2014 |
Deficient endocannabinoid signaling in the central amygdala contributes to alcohol dependence-related anxiety-like behavior and excessive alcohol intake A Serrano, FJ Pavon, MW Buczynski, J Schlosburg, LA Natividad, IY Polis, ... Neuropsychopharmacology 43 (9), 1840-1850, 2018 | 67 | 2018 |
Oleoylethanolamide, neuroinflammation, and alcohol abuse L Orio, F Alen, FJ Pavón, A Serrano, B García-Bueno Frontiers in Molecular Neuroscience, 490, 2019 | 65 | 2019 |
Anti‐obesity efficacy of LH‐21, a cannabinoid CB1 receptor antagonist with poor brain penetration, in diet‐induced obese rats M Alonso, A Serrano, M Vida, A Crespillo, L Hernandez‐Folgado, ... British journal of pharmacology 165 (7), 2274-2291, 2012 | 65 | 2012 |
Effects of the endogenous PPAR‐α agonist, oleoylethanolamide on MDMA‐induced cognitive deficits in mice A Plaza‐Zabala, F Berrendero, J Suarez, FJ Bermudez‐Silva, ... Synapse 64 (5), 379-389, 2010 | 58 | 2010 |
Pharmacological blockade of either cannabinoid CB1 or CB2 receptors prevents both cocaine-induced conditioned locomotion and cocaine-induced reduction of … E Blanco-Calvo, P Rivera, S Arrabal, A Vargas, FJ Pavón, A Serrano, ... Frontiers in integrative neuroscience 7, 106, 2014 | 52 | 2014 |